Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works

Comprehensive genomic characterization of squamous cell lung cancers

The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994 · see citing works

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · see citing works

A note on quantifying follow-up in studies of failure time

SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592 · see citing works

Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer

The International Adjuvant Lung Cancer Trial Collaborative Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,334 · see citing works

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Winton, T. L., Livingston, R. B., Johnson, D. H., Rigas, J. R., Johnston, M., Butts, C. A., Cormier, Y. F., Goss, G., Inculet, R., Vallières, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810 · see citing works

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Douillard, J., Rosell, R., Lena, M. D., Carpagnano, F., Ramlau, R., González-Larriba, J. L., Grodzki, T., Pereira, J. R., Groumellec, A. L., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573 · see citing works

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4855 · Cited by 973 · see citing works

Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 877 · see citing works

K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung

Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., van Zandwijk, N., Mooi, W. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230902 · Cited by 806 · see citing works

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noël, S., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 604 · see citing works

An Unidentified Virus which causes the Rapid Production of Tumours in Mice

Harvey, J. J. (1964) · Nature · doi:10.1038/2041104b0 · Cited by 554 · see citing works

Mutational Activation of the K-rasOncogene

Rodenhuis, S., van de Wetering, M. L., Mooi, W. J., Evers, S. G., van Zandwijk, N., & Bos, J. L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171504 · Cited by 532 · see citing works

A Genomics-Based Classification of Human Lung Tumors

Thomas, R. K., Buettner, R., & Wolf, J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 508 · see citing works

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466 · see citing works

Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

Butts, C. A., Ding, K., Seymour, L., Twumasi‐Ankrah, P., Graham, B., Gandara, D. R., Johnson, D. H., Kesler, K. A., Green, M., Vincent, M. D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0333 · Cited by 425 · see citing works

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

Arriagada, R., Dunant, A., Pignon, J., Bergman, B., Chabowski, M., Grunenwald, D. H., Kozłowski, M., Pechoux, C. L., Pirker, R., Pinel, M. I. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2272 · Cited by 394 · see citing works

Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Shepherd, F. A., Domerg, C., Hainaut, P. L., Janne, P. A., Pignon, J., Graziano, S. L., Douillard, J.-Y., Brambilla, E., Chevalier, T. L., Seymour, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1390 · Cited by 294 · see citing works

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

Kosaka, T., Yatabe, Y., Onozato, R., Kuwano, H., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181914111 · Cited by 253 · see citing works

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 241 · see citing works

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230 · see citing works

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173 · see citing works

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases

Huncharek, M. S. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1507 · Cited by 173 · see citing works

Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells

Yang, L., Zhou, Y., Li, Y., Zhou, J., Wu, Y., Cui, Y., Yang, G. S., & Hong, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.003 · Cited by 133 · see citing works

Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort

Scoccianti, C., Vesin, A., Martel, G., Olivier, M., Brambilla, E. M., Timsit, J., Tavecchio, L., Brambilla, C., Field, J. K., & Hainaut, P. L. (2012) · European Respiratory Journal · doi:10.1183/09031936.00097311 · Cited by 116 · see citing works

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

Ma, X., Teuff, G. L., Lacas, B., Tsao, M., Graziano, S. L., Pignon, J., Douillard, J.-Y., Chevalier, T. L., Seymour, L., Filipits, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.002 · Cited by 100 · see citing works

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

Rodenhuis, S., Boerrigter, L., Top, B., Slebos, R. J. C., Mooi, W. J., Veer, L. V., & van Zandwijk, N. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.285 · Cited by 92 · see citing works

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Wang, Z., & Fang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s69690 · Cited by 75 · see citing works

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma

Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3727 · Cited by 73 · see citing works

Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.

Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., Kinoshita, M., Hadama, T., & Miyake, M. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.3.553 · Cited by 72 · see citing works

Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis

Zhang, Z., Wang, T., Zhang, J., Cai, X., Pan, C., Yu, L., Chen, J., Zhou, C., & Yin, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106053 · Cited by 65 · see citing works

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

Lim, S. M., Kim, H. R., Cho, E. K., Min, Y. J., Ahn, J. S., Ahn, M., Park, K., Cho, B. C., Lee, J.-H., Jeong, H. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8904 · Cited by 48 · see citing works

Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer

Ma, X., Rousseau, V., Sun, H., Lantuéjoul, S., Filipits, M., Pirker, R., Popper, H., Mendiboure, J., Vataire, A. L., Chevalier, T. L., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.015 · Cited by 42 · see citing works

Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas

Cortot, A. B., Younes, M., Martel-Planche, G., Guibert, B., Isaac, S., Souquet, P.-J., Commo, F., Girard, P., Fouret, P. J., Brambilla, E. M., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.08.003 · Cited by 18 · see citing works

Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers.

Yu, H. A., Jordan, E., Ni, A., Feldman, D., Rodríguez, C., Kim, H. R., Kris, M. G., Solit, D. B., Berger, M. F., Ladanyi, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9053 · Cited by 13 · see citing works

Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé, C., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Pintilie, M., Leighl, N. B., Feld, R. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.11585 · Cited by 6 · see citing works

Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC).

Jao, K., Tomasini, P., Kamel‐Reid, S., Tsao, M., Korpanty, G. J., Mascaux, C., Liu, G., Leighl, N. B., Feld, R. D., Bradbury, P. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.7521 · Cited by 4 · see citing works

Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).

Tomasini, P., Jao, K., Kamel‐Reid, S., Stockley, T. L., Tsao, M., Liu, G., Leighl, N. B., Feld, R. D., Bradbury, P. A., Pintilie, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11060 · Cited by 3 · see citing works

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Xu, J., Zhang, C., Wang, X., Zhai, L., Ma, Y., Mao, Y., Qian, K., Sun, C., Liu, Z., Jiang, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.043 · Cited by 612 · see citing works

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466 · see citing works

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · see citing works

Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

Devarakonda, S. H. K., Rotolo, F., Tsao, M., Lanc, I., Brambilla, E. M., Masood, A., Olaussen, K. A., Fulton, R. S., Sakashita, S., Leer, A. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1963 · Cited by 272 · see citing works

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230 · see citing works

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.033 · Cited by 167 · see citing works

The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base

Jiao, X., Qin, B., You, P., Cai, J. Q., & Zang, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.003 · Cited by 182 · see citing works

Drugging KRAS: Current perspectives and state-of-art review

Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 163 · see citing works

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Yu, L., & Zhang, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-06805-5 · Cited by 160 · see citing works

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 132 · see citing works

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing

Lim, T. K. H., Skoulidis, F., Kerr, K. M., Ahn, M., Kapp, J. R., Soares, F. A., & Yatabe, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107293 · Cited by 126 · see citing works

Current therapy of KRAS-mutant lung cancer

Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115 · see citing works

Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC

Saleh, M. M., Scheffler, M., Merkelbach‐Bruse, S., Scheel, A. H., Ulmer, B., Wolf, J., & Buettner, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.764 · Cited by 77 · see citing works

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Liu, S., Bao, H., Wang, Q., Mao, W., Chen, Y., Tong, X., Xu, S.-T., Wu, L., Wei, Y., Liu, Y.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26806-7 · Cited by 77 · see citing works

KRAS in NSCLC: State of the Art and Future Perspectives

Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76 · see citing works

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Hobor, S., Bakir, M. A., Hiley, C. T., Skrzypski, M. T., Frankell, A. M., Bakker, B., Watkins, T. B. K., Markovets, A. A., Dry, J. R., Brown, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47606-9 · Cited by 51 · see citing works

Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature

Karimpour, M., Gavgani, R. R., Maydanchi, M., Rajabi, A., Azizi, F., & Saber, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112190 · Cited by 46 · see citing works

Prognostic value of KRAS/TP53/PIK3CA in non‑small cell lung cancer

Zhao, J., Han, Y., Li, J., Chai, R., & Bai, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10012 · Cited by 45 · see citing works

Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual

Wu, L., Liu, X., Jiang, W., Huang, W., Lin, P., Long, H., Zhang, L., & Ma, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00571 · Cited by 44 · see citing works

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer

Jao, K., Tomasini, P., Kamel‐Reid, S., Korpanty, G. J., Mascaux, C., Sakashita, S., Labbé, C., Leighl, N. B., Liu, G., Feld, R. D., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.023 · Cited by 40 · see citing works

Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations

Passaro, A., Mok, T. S. K., Attili, I., Wu, Y.-L. L. C., Tsuboi, M., de Marinis, F., & Peters, S. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0459 · Cited by 36 · see citing works

Tartrate-Resistant Acid Phosphatase 5/ACP5 Interacts with p53 to Control the Expression of SMAD3 in Lung Adenocarcinoma

Hu, Y., Yu, J., Wang, Q., Zhang, L., Chen, X., Cao, Y., Zhao, J., Xu, Y., Jiang, D., Wang, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.01.010 · Cited by 36 · see citing works

Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma

Kim, I. A., Hur, J. Y., Kim, H. J., Park, J. H., Hwang, J. J., Lee, S. A., Lee, S. E., Kim, W. S., & Lee, K. Y. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09276-x · Cited by 36 · see citing works

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

Michels, S. Y. F., Heydt, C., van Veggel, B. A. M. H., Deschler-Baier, B., Pardo, N., Monkhorst, K., Rüsseler, V., Stratmann, J., Griesinger, F., Steinhauser, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00210 · Cited by 36 · see citing works

TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients

Xue, D., Lin, H., Lin, L., Wei, Q., Yang, S., & Chen, X. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2568 · Cited by 35 · see citing works

The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer

Choudhury, N. J., Lavery, J. A., Brown, S., de Bruijn, I., Jee, J., Tran, T. N., Rizvi, H. A., Arbour, K. C., Whiting, K. A., Shen, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0580 · Cited by 34 · see citing works

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer

Tsakonas, G., Botling, J., Micke, P., Rivard, C. J., Fleur, L. L., Mattsson, J. S. M., Boyle, T., Hirsch, F. R., & Ekman, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.028 · Cited by 29 · see citing works

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis

Zheng, C. J., Li, X., Ren, Y., Yin, Z., & Zhou, B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00030 · Cited by 28 · see citing works

Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer

Mathiot, L., Nigen, B., Goronflot, T., Hiret, S., Doucet, L. S., Tostivint, E. P., Bennouna, J., Denis, M. G., Herbreteau, G., & Raimbourg, J. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.12.004 · Cited by 26 · see citing works

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

Seymour, L., Teuff, G. L., Brambilla, E. M., Shepherd, F. A., Soria, J., Kratzke, R. A., Graziano, S. L., Douillard, J.-Y., Rosell, R., Reiman, T., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.001 · Cited by 26 · see citing works

Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients

Nong, L., Zhang, Z., Xiong, Y., Zheng, Y., Li, X., Li, D., He, Q., & Li, T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.12.25 · Cited by 26 · see citing works

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges

Remón, J., Saw, S. P. L., Cortiula, F., Singh, P. K., Menis, J., Mountzios, G., & Hendriks, L. E. L. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1451 · Cited by 26 · see citing works

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Rosen, J. C., Weiss, J., Pham, N., Li, Q., Martins-Filho, S. N., Wang, Y., Tsao, M., & Moghal, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101179 · Cited by 25 · see citing works

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies

Liguori, L., Salomone, F., Viggiano, A., Sabbatino, F., Pepe, S., Formisano, L., Bianco, R., & Servetto, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104554 · Cited by 25 · see citing works

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies

Rajurkar, S. P., Mambetsariev, I., Pharaon, R. R., Leach, B., Tan, T., Kulkarni, P., & Salgia, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061870 · Cited by 25 · see citing works

p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1

Lv, T., Lv, H., Fei, J., Xie, Y., Lian, D., Hu, J. Y., Tang, L., Shi, X., Wang, J., Zhang, S., et al. (2020) · Journal of Cancer · doi:10.7150/jca.44718 · Cited by 24 · see citing works

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Le, X., Molife, C., Leusch, M. S., Rizzo, M. T., Peterson, P. M., Caria, N., Chen, Y., González-Gugel, E., & Visseren‐Grul, C. (2022) · Cancers · doi:10.3390/cancers14246127 · Cited by 25 · see citing works

Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma

Kneuertz, P. J., Carbone, D. P., D’Souza, D. M., Shilo, K., Abdel‐Rasoul, M., Zhao, W., Williams, T. M., Jones, D. R., & Merritt, R. E. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.012 · Cited by 23 · see citing works

The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis

Zhang, R., Tian, P., Chen, B., Wang, T., & Li, W. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1585690 · Cited by 23 · see citing works

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer

Tomasini, P., Mascaux, C., Jao, K., Labbe, C., Kamel-Reid, S., Stockley, T., Hwang, D. M., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.009 · Cited by 22 · see citing works

Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis

Ryu, J., Lim, J. H., Lee, M. K., Lee, S. J., Kim, H.-J., Kim, M. J., Park, M. H., Kim, J. S., Nam, H., Park, N., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0147 · Cited by 22 · see citing works

The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study

Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., Lund‐Iversen, M., Brustugun, O. T., Førde, D., Paulsen, E., et al. (2021) · Cancers · doi:10.3390/cancers13174294 · Cited by 21 · see citing works

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis

Zhao, Y., Pan, Y., Cheng, C., Zheng, D., Zhang, Y., Gao, Z., Fu, F., Li, H., Zheng, S., Zhuge, L., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03237-3 · Cited by 20 · see citing works

Definitive evidence for Club cells as progenitors for mutant Kras/Trp53‐deficient lung cancer

Rosigkeit, S., Kruchem, M., Thies, D., Kreft, A., Eichler, E., Boegel, S., Jansky, S., Siegl, D., Kaps, L., Pickert, G., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33756 · Cited by 20 · see citing works

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy

Takahashi, T., Sakai, K., Kenmotsu, H., Yoh, K., Daga, H., Ohira, T., Ueno, T., Aoki, T., Hayashi, H., Yamazaki, K., et al. (2021) · Cancer Science · doi:10.1111/cas.15171 · Cited by 20 · see citing works

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

Peng, L., Guo, J., Kong, L., Huang, Y., Tang, N., Zhang, J., Wang, M., He, X., Li, Z., Peng, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070761 · Cited by 19 · see citing works

Lung Cancer Staging and Associated Genetic and Epigenetic Events.

Kim, D., Lee, Y., Kim, D.-H., & Bae, S. (2020) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2020.2246 · Cited by 18 · see citing works

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

Szlosarek, P. W., Wimalasingham, A. G., Phillips, M. M., Hall, P. E., Chan, P. Y., Conibear, J., Lim, L., Rashid, S., Steele, J. P. C., Wells, P., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4196 · Cited by 17 · see citing works

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

Zheng, Y.-K., Zhou, Z.-S., Wang, G.-Z., Tu, J., Cheng, H., Ma, S.-Z., Ke, C., Wang, Y., Jian, Q., Shu, Y.-H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05761-9 · Cited by 18 · see citing works

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients

Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 17 · see citing works

Single- and multi-site radiomics may improve overall survival prediction for patients with metastatic lung adenocarcinoma.

Masson-Grehaigne, C., Lafon, M., Palussière, J., Leroy, L., Bonhomme, B., Jambon, E., Italiano, A., Cousin, S., & Crombé, A. (2024) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2024.07.005 · Cited by 17 · see citing works

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer

Rotolo, F., Zhu, C., Brambilla, E. M., Graziano, S. L., Olaussen, K. A., Chevalier, T. L., Pignon, J., Kratzke, R. A., Soria, J., Shepherd, F. A., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.05.01 · Cited by 16 · see citing works

Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma

Liu, D., Zhao, Z.-R., Lin, Y., Zhou, W., Hou, J., Ye, Z., & Long, H. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07254-6 · Cited by 16 · see citing works

Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study

Tamiya, A., Koh, Y., Isa, S., Kubo, A., Ando, M., Saka, H., Yoshimoto, N., Takeo, S., Adachi, H., Tagawa, T., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2897 · Cited by 15 · see citing works

A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients

Liu, Y., Wu, A., Li, X., Wang, S., Fang, S., & Mo, Y. (2021) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2021.06.030 · Cited by 15 · see citing works

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer

Li, Y., Hu, L., Peng, X., Xu, H., Tang, B., & Xu, C. S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.102 · Cited by 13 · see citing works

Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53

Ghaleb, A. M., Yallowitz, A. R., & Marchenko, N. D. (2019) · Communications Biology · doi:10.1038/s42003-019-0669-y · Cited by 13 · see citing works

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

on behalf of the LACE-Bio Collaborative Group, Fung, A. S., Karimi, M., Michiels, S., Seymour, L., Brambilla, E. M., Chevalier, T. L., Soria, J., Kratzke, R. A., Graziano, S. L., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-927 · Cited by 12 · see citing works

A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells

Zhou, H., Xu, L., Shi, Y., Gu, S., Wu, N., Liu, F., Huang, Y., Qian, Z., Xue, W., Wang, X., et al. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00483 · Cited by 12 · see citing works

Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer

Wang, Y., Wang, Z., Piha-Paul, S. A., Jankú, F., Subbiah, V., Shi, N., Hess, K. R., Broaddus, R. R., Shan, B., Naing, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25947 · Cited by 11 · see citing works

Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 11 · see citing works

Targeting Molecular Alterations in Non-Small-Cell Lung Cancer: What’s Next?

Castro, R. L., García-Peña, T., Mielgo-Rubio, X., Riudavets, M., Teixidó, C., Vilariño, N., Couñago, F., & Mezquita, L. (2022) · Personalized Medicine · doi:10.2217/pme-2021-0059 · Cited by 10 · see citing works

STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial

Oudart, J., Garinet, S., Leger, C., Barlési, F., Mazières, J., Jeannin, G., Audigier-Valette, C., Moro‐Sibilot, D., Langlais, A., Amour, E., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107508 · Cited by 9 · see citing works

Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma

Xu, Y., Yang, Y., Wang, Y., Su, J., Chan, T., Zhou, J., Gong, Y., Wang, K., Gu, Y., Zhang, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04099-2 · Cited by 8 · see citing works

Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer

Wang, X., Hou, K., Ricciuti, B., Alessi, J. V., Li, X., Pecci, F., Dey, R., Luo, J., Awad, M. M., Gusev, A., et al. (2024) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2024.100320 · Cited by 7 · see citing works

Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: a systematic review and meta-analysis

Soon, Y. Y., Vellayappan, B. A., Tey, J. C. S., Leong, C. N., Koh, W. Y., & Tham, I. W. K. (2017) · Oncotarget · doi:10.18632/oncotarget.21019 · Cited by 7 · see citing works

Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data

Kumar, P. A., Karimi, M., Basnet, A., Seymour, L., Kratzke, R. A., Brambilla, E., Chevalier, T. L., Soria, J., Olaussen, K. A., Devarakonda, S. H. K., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.06.002 · Cited by 6 · see citing works

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

Kanemura, H., Yokoyama, T., Nakajima, R., Nakamura, A., Kuroda, H., Kitamura, Y., Shoda, H., Mamesaya, N., Miyata, Y., Okamoto, T., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100658 · Cited by 6 · see citing works

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

Zhang, S. S., & Ou, S. I. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s358902 · Cited by 6 · see citing works

Development and validation of a mutation-annotated prognostic score for intrahepatic cholangiocarcinoma after resection: a retrospective cohort study

Wang, X., Zhu, W., Lu, L., Li, Y., Zhu, Y., Yang, L., Sun, H., Wang, C., Lin, J., Huang, C., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000636 · Cited by 5 · see citing works

Clinical characteristics and prognostic value of EGFR mutation in stage I lung adenocarcinoma with spread through air spaces after surgical resection

Mao-Gang, G. A. O., Wang, S., Han, K.-H., Xie, S.-N., & Liu, Q. (2022) · Neoplasma · doi:10.4149/neo_2022_220619n649 · Cited by 5 · see citing works

A Comprehensive Search of Non-Canonical Proteins in Non-Small Cell Lung Cancer and Their Impact on the Immune Response

Irajizad, E., Fahrmann, J. F., Long, J. P., Vykoukal, J. V., Kobayashi, M., Capello, M., Yu, C., Cai, Y., Hsiao, F. C., Patel, N. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168933 · Cited by 4 · see citing works

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Lazar, V., Girard, N., Raymond, É., Martini, J.-F., Galbraith, S. M., Raynaud, J., Bresson, C., Solomon, B. M., Magidi, S., Nechushtan, H., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00072 · Cited by 4 · see citing works

Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations

Ghazali, N., Feng, J., Hueniken, K., Khan, K., Balaratnam, K., Waddell, T. K., Yasufuku, K., Pierre, A. F., Donahoe, L. L., Wakeam, E., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308466 · Cited by 4 · see citing works

Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations

Feng, J., Hueniken, K., Fan, Z. J., Zhan, L. J., Faour, E., Corke, L., Alghabban, A., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108452 · Cited by 4 · see citing works

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort

Rúgolo, J. R. M., Baldavira, C. M., Prieto, T. G., Olivieri, E. H. R., Fabro, A. T., Rainho, C. A., Castelli, E. C., Ribolla, P. E. M., Ab’Saber, A. M., Takagaki, T. Y., et al. (2023) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2023e12488 · Cited by 4 · see citing works

Type of TP53 mutation influences oncogenic potential and spectrum of associated K‐ras mutations in lung‐specific transgenic mice

Duan, W., Gao, L., Kalvala, A., Aguila, B., Brooks, C., Mo, X. M., Ding, H., Shilo, K., Otterson, G. A., & Villalona-Calero, M. A. (2019) · International Journal of Cancer · doi:10.1002/ijc.32279 · Cited by 4 · see citing works

Genetic analyses of differences between solid and nonsolid predominant lung adenocarcinomas

Luo, J., Ma, K., Shi, Y., Chen, Z., Zhao, M., Huang, Y., Wang, S., Xi, J., Zhan, C., Xu, L., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12876 · Cited by 4 · see citing works

The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer

Zhao, X., Zheng, Y., Wang, Y., Zhang, M., Dong, Z., Liu, Y., & Sun, M. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s484209 · Cited by 4 · see citing works

Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma

Masuda, T., Katsumata, S., Isaka, M., Serizawa, M., Kawata, T., 桃子, 浅., Yamaguchi, D., Matsushima, K., Hayasaka, K., Kojima, H., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.009 · Cited by 3 · see citing works

Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer

Wang, M., Li, P., Wan, R., & Liu, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.051 · Cited by 3 · see citing works

Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma

Taus, Á., Camacho, L., Rocha, P., Hernández, A., Longarón, R., Clavé, S., Fernández‐Ibarrondo, L., Salido, M., Hardy-Werbin, M., Fernández‐Rodríguez, C., et al. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2020.01.023 · Cited by 3 · see citing works

Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study

Safi, S., Krzykalla, J., Hoffmann, H., Benner, A., Bischoff, H. G., Eichhorn, M., Kriegsmann, M., Poschke, I. C., Stögbauer, F., Umansky, L., et al. (2024) · Pulmonology · doi:10.1016/j.pulmoe.2024.03.003 · Cited by 3 · see citing works

[Dynamic Changes of Circulating Tumor DNA in Peripheral Blood Predict the Efficacy of TKI in the Treatment of Lung Adenocarcinoma with EGFR Mutation].

Song, Y., Wang, S., Zhao, Y., Jiang, N., Qiao, G., Zhao, J., Di, Y., Wang, X., & Ren, J. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.03 · Cited by 3 · see citing works

Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma

Taus, Á., Camacho, L., Rocha, P., Hernández, A., Longarón, R., Clavé, S., Fernández‐Ibarrondo, L., Salido, M., Hardy-Werbin, M., Fernández‐Rodríguez, C., et al. (2021) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2020.01.013 · Cited by 3 · see citing works

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project

Molina-Vila, M. A., Tsourti, Z., Vervita, K., Bertrán-Alamillo, J., García‐Peláez, B., Kerr, K. M., Bubendorf, L., Madsen, L. B., Biernat, W., Stenzinger, A., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116583 · Cited by 2 · see citing works

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC

Canaslan, K., Başbınar, Y., & Öztop, İ. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105344 · Cited by 2 · see citing works

The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma

Li, J. J., Wu, X. J., Farzin, M., Bray, V., Williamson, J., Pal, A., Yip, P. Y., Hagelamin, A., Ding, P., Nindra, U., et al. (2024) · Pathology · doi:10.1016/j.pathol.2024.04.002 · Cited by 2 · see citing works

Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

Chen, S., Fu, A., Lu, Y., Lu, W., Chen, Y., Hong, S., Zhou, S., Xiang, T., Zhang, Z., & Cai, Y. (2022) · BMC Genomics · doi:10.1186/s12864-021-08289-4 · Cited by 2 · see citing works

Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence

Esfahanian, N., Chan, S. W. S., Zhan, L. J., Brown, M. C., Khan, K., Lee, J., Balaratnam, K., Yan, E., Parker, J., García-Pardo, M., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100774 · Cited by 2 · see citing works

Clinical Thoughts on the Predictive Value of the Newly Proposed Grading System of Invasive Pulmonary Adenocarcinoma

Li, S., Deng, J., She, Y., Hou, L., & Chen, C. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.006 · Cited by 2 · see citing works

Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer

Libby, D. M., Libby, L. J., Ma, X., Chua, J. M. W., Blow, T., Razavi, P., & Saxena, A. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.10.016 · Cited by 1 · see citing works

Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II–III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study

Hamada, A., Takamori, S., Hashinokuchi, A., Shimokawa, M., Suda, K., Katsumata, S., Haratake, N., Nomura, K., Shimada, Y., Toyoda, T., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20626-z · Cited by 1 · see citing works

LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC

Lee, R. C., Thapa, B., & John, T. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.01 · Cited by 1 · see citing works

Meet the new boss: lung cancer staging

Begnaud, A., & Kratzke, R. A. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.89 · Cited by 1 · see citing works

Visiting an old foe: distant recurrence following R0 lobectomy for pathological N0 lung adenocarcinoma

Hirji, S. A., & D’Amico, T. A. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.116

KRAS-Mutated Lung Cancer

Basu, A., & Nieva, J. J. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_10

p53-Hsp90 Axis in Human Cancer

Ghaleb, A. M., & Marchenko, N. D. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_7

ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma

Long, H., & Liu, D. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08079-z

Prognostic effect of TP53 mutation combined with EGFR mutation or KRAS mutation on non-small cell lung cancer.

Li, Y., Jiang, D., Niu, X., Zhou, X., Hong, L., Cui, Y., Shi, K., Jin, H. M., Zhang, X., Huang, F., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.e21046 · Cited by 3 · see citing works

P2.06.10 Title: Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-Small Cell Lung Cancer: A cBioPortal Analysis

Chukkalore, D., Aung, W. Y., Cheranda, N. K., Puttagunta, N., Singhal, A., Chiang, I., & Seetharamu, N. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.09.544

Prognostic and Predictive Values of KRAS in EGFR-Based Subgroups and Combined With p53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): A Lace-Bio Study

Janne, P. A., Shepherd, F. A., Domerg, C., Teuff, G. L., Kratzke, R. A., Hainaut, P. L., Pignon, J., Rosell, R., Soria, J., & Tsao, M. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32761-7 · Cited by 5 · see citing works

Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)

Scheffler, M., Frank, R., Ihle, M. A., Abdulla, D., Koleczko, S., Nogová, L., Holzem, A. M. E., Chanra, T., Riedel, R. F., Michels, S. Y. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz063.045

The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis

Zhang, R., Tian, P., Chen, B., Wang, T., & Li, W. (2019) · Figshare · doi:10.6084/m9.figshare.7851713